Document is current
Any future updates will be listed below
-
Authors
Molenaar, Pam C. G. https://orcid.org/0000-0002-4735-539X
Noteboom, Samantha https://orcid.org/0000-0003-4796-8636
van Nederpelt, David R.
Krijnen, Eva A. https://orcid.org/0000-0002-3628-4127
Jelgerhuis, Julia R.
Lam, Ka-Hoo https://orcid.org/0000-0003-0926-1445
Druijff-van de Woestijne, Gerrieke B.
Meijer, Kim A. https://orcid.org/0000-0003-0416-1488
van Oirschot, Pim https://orcid.org/0000-0003-1135-0500
de Jong, Brigit A.
Brouwer, Iman https://orcid.org/0000-0002-0408-0461
Jasperse, Bas
de Groot, Vincent https://orcid.org/0000-0002-6073-6250
Uitdehaag, Bernard M. J. https://orcid.org/0000-0002-9226-7364
Schoonheim, Menno M. https://orcid.org/0000-0002-2504-6959
Strijbis, Eva M. M. https://orcid.org/0000-0001-6705-5864
Killestein, Joep https://orcid.org/0000-0002-6347-5957
-
Funding
Funding for this research was provided by:
Biogen (Unrestricted funding)
Health~Holland (Grant No. LSHM16060-SGF)
Stichting MS Research (Grant No. 16-946 MS)
- License Information
-
More Information
Article History
Received: 19 March 2024
Revised: 8 June 2024
Accepted: 10 June 2024
First Online: 15 July 2024
Declarations
:
: P.C.G. Molenaar has nothing to disclose. S. Noteboom is supported by research grants from Atara Biotherapeutics, Merck and Biogen. D.R. van Nederpelt has nothing to disclose. E.A. Krijnen has nothing to disclose. J.R. Jelgerhuis has nothing to disclose. K.H. Lam has nothing to disclose. G.B. Druijff-van de Woestijne and K.A. Meijer are employees of Neurocast B.V. P. van Oirschot is an employee of Sherpa B.V., manufacturer of the MS sherpa app. I. B.A. de Jong has nothing to disclose. Brouwer received research support from Merck, Novartis, Teva, and the Dutch MS Research Foundation. B. Jasperse has nothing to disclose. V. de Groot has nothing to disclose. B.M.J. Uitdehaag has received research support and/or consultancy fees from Biogen Idec, Genzyme, Merck, Serono, Novartis, Roche, Teva and Immunic Therapeutics. M.M. Schoonheim serves on the editorial board of Neurology and Frontiers in Neurology, receives research support from the Dutch MS Research Foundation, Eurostars-EUREKA, ARSEP, Amsterdam Neuroscience, MAGNIMS and ZonMW (Vidi grant, project number 09150172010056) and has served as a consultant for or received research support from Atara Biotherapeutics, Biogen, Celgene/Bristol Meyers Squibb, EIP, Sanofi, MedDay and Merck. E.M.M. Strijbis has nothing to disclose. J. Killestein received research grants for multicentre investigator initiated trials DOT-MS trial, ClinicalTrials. gov Identifier: NCT04260711 (ZonMW) and BLOOMS trial (ZonMW and Treatmeds), ClinicalTrials. gov Identifier: NCT05296161); received consulting fees for F. Hoffmann-La Roche, Biogen, Teva, Merck, Novartis and Sanofi/Genzyme (all payments to institution); reports speaker relationships with F. Hoffmann-La Roche, Biogen, Immunic, Teva, Merck, Novartis and Sanofi/Genzyme (all payments to institution); adjudication committee of MS clinical trial of Immunic (payments to institution only).
: The APPS-MS study was approved by the medical research ethics committee of the VUmc (reference 2017.576) and was registered at the Netherlands Trial Register (trial number NTR7268).
